Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anti-Pain Drugs Licensed To Lilly Boost Glenmark Earnings

This article was originally published in PharmAsia News

Executive Summary

NEW DELHI - Glenmark Pharmaceuticals said it expects further earnings gains from a portfolio of anti-pain drugs licensed to Eli Lilly and from products in its pipeline as it reorganizes its business into specialty and generic units
Advertisement

Related Content

Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
Glenmark’s Novel Molecule For Neuropathic Pain, Osteoarthritis To Enter Phase I Trials
Ranbaxy Delays Spin Off Of R&D Unit Until Later This Year
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Lilly Acquires Rights To TRPV-1 Receptor Antagonists From Glenmark
Advertisement
UsernamePublicRestriction

Register

SC066688

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel